Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | KRAS | P01116 | 4/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30475587 | 0.89 | HTR7 (0.42) | HTR2AHTR2CHTR7DGAT1PRMT5 | |
| SCHEMBL8252347 | 0.89 | HTR7 (0.42) | HTR2AHTR2CHTR7DGAT1PRMT5 | |
| Indole SCHEMBL28953075 | 0.86 | HTR2A (0.38) | HTR2AHTR2CHTR7DGAT1NTSR1 | |
| SCHEMBL29925168 | 0.84 | HTR2C (0.48) | HTR2AHTR2CDGAT1ROCK1PRMT5 | |
| SCHEMBL28840671 | 0.84 | HTR2C (0.48) | HTR2AHTR2CDGAT1ROCK1PRMT5 | |
| SCHEMBL4493915 | 0.83 | HTR2C (0.49) | HTR2AHTR2CDGAT1PRMT5NPC1 | |
| SCHEMBL29924561 | 0.83 | HTR2C (0.51) | HTR2AHTR2CSLC6A2ROCK1PRMT5 | |
| SCHEMBL29924782 | 0.83 | HTR2C (0.49) | HTR2AHTR2CDGAT1SLC6A2KRAS | |
| SCHEMBL28840665 | 0.83 | HTR2C (0.49) | HTR2AHTR2CDGAT1SLC6A2KRAS | |
| SCHEMBL28840999 | 0.83 | DGAT1 (0.36) | HTR2AHTR2CDGAT1KRASNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028655-B | 2-trifluoromethyl-3-iodo-indole compound and preparation method thereof | 上海大学 | 2024-01-16 | — | — | CN | claimed |
| CN-115028655-A | 2-trifluoromethyl-3-iodine-indole compound and preparation method thereof | 上海大学 | 2022-09-09 | — | — | CN | claimed |
| CN-115028655-B | 2-trifluoromethyl-3-iodo-indole compound and preparation method thereof | 上海大学 | 2024-01-16 | — | — | CN | disclosed |
| CN-116745278-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-115028655-A | 2-trifluoromethyl-3-iodine-indole compound and preparation method thereof | 上海大学 | 2022-09-09 | — | — | CN | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| US-20190337921-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3544956-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | Eisai R&D Management Co., Ltd. (JP) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098251-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089493-A1 | PYRROLE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089493-A1 | PYRROLE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| EP-1751124-A2 | RAF MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112932-A2 | RAF MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009488-A1 | Raf Modulators and Methods of Use | BRAF, RAF1, ARAF | HTR2A 4668/4885HTR2C 4730/4885HTR7 4466/4885 |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | BRAF, RAF1, ARAF | HTR2A 4330/4885HTR2C 4552/4885HTR7 4293/4885 |
| US-20190337921-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | HTR2A 3862/4885HTR2C 3880/4885HTR7 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.